CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates Entered into ...

GSK and CureVac will together receive $740 million, as well as royalties on sales of COVID-19 vaccines in the US ...

CureVac ( (CVAC) ) has issued an update. CureVac N.V. released its unaudited interim condensed consolidated financial statements for the period ending June 30, 2025, revealing a substantial decline ...

GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review ...

Pfizer's inclacumab fails Phase III study for sickle cell disease, disappointing the community while the company remains ...

CureVac ( (CVAC)) has provided an announcement. On August 7, 2025, CureVac announced the resolution of U.S. patent litigation with Pfizer/BioNTech concerning mRNA-based COVID-19 vaccines. As part of ...

Cash and cash equivalents amounted to EUR 392.7 million at the end of June 2025, decreasing from EUR 481.7 million at the end of 2024. In the ...

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

New members to the Access Advance patent pool and Harvard University coming under fire were also among the top talking points ...

Shortly after that, the CDC overhauled its vaccine recommendations in COVID, nixing its endorsement of the shots for pregnant women and healthy children. At the time, RFK Jr. said he “couldn’t be more ...

This episode of Pharma Pulse explores the FDA’s new proactive quality review initiative for drug manufacturing, GSK’s $370 ...